CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Using emergency funds to pay off credit card debt can be tempting but may leave you vulnerable. Weigh the pros and cons to make the best decision.
23,601 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Icon stock crushed Wednesday as the CRO leader posted a stronger quarter than expected. We break down what drove the ...
Two heavyweights vie for leadership in AI cooling and data-center resilience. This guide breaks down which stock—NVEN...
Teladoc has faced a challenging stretch after its pandemic boom. This guide examines whether teladoc stock going read...
As 2025 unfolds, MediWound faces a pivotal year for debt, cash, and milestones. This analysis breaks down what mediwo...
Figuring out what considered good stock dividends means looking beyond yield. This article breaks down the metrics th...
3D Systems' Q1 2026 update sheds light on demand, margins, and cash flow across its printing systems, materials, and ...
As market focus shifts away from growth labels, three legacy automakers stand out for retirees seeking cash flow and ...
SanDisk has surged about 500% in 2026 on AI-driven NAND demand. Yet the stock faces a deeply concerning risk: depende...
Retirees are shifting toward stable, long-running income. This report explains why high-yielding dividend kings retir...
SpaceX has dazzled investors, but big bets come with big risks. This article explains three reasons reasons spacex st...
With rate-cut bets disappearing, traders pivot to potential rate hikes and Bitcoin’s role as a long-term hedge agains...